Pegasus Biotech Inc. has announced a major breakthrough in the field of biopharmaceutical and vaccine development, with the launch of their new BPE plasmid technology. This innovative technology enables precise control over when and how DNA is produced, resulting in significantly higher replication levels compared to existing methods.
Dr. Patrick Slaine, the lead scientist behind this project, stated that they have redesigned how plasmid DNA replicates, using a patented origin that can lay dormant during fermentation and trigger replication at high cell densities. This approach allows for more efficient use of resources and minimizes the risk of contamination, making it an ideal choice for applications where cost of goods sold and patient safety are paramount.
In addition to its efficiency and reliability, the BPE plasmid technology also offers enhanced expression, with cells transfected with this plasmid showing up to 7 times more expression than conventional backbones. This makes it an attractive option for researchers looking to develop new drugs or vaccines quickly and efficiently.
Pegasus Biotech’s COO, Daniel Wilson, emphasized the transformational nature of this technology and its potential to revolutionize the industry. He noted that this project required low cost, minimal bacterial sequences, high expression, and no antibiotic resistance selection marker – all of which are characteristics of this technology.
With its expertise in vaccine and biopharmaceutical development, Pegasus Biotech is well-positioned to facilitate the development and market entry of innovative products in this space. They offer a range of services including seed-to-formulation process development and associated analytical development to ensure client projects comply with global regulations and result in commercially viable products. For more information on Pegasus’ services visit their website or contact them directly via email or visit www.pegasusbio.com for media inquiries.